Mr Gregory Mark Coleman, OTR | |
59 Timber Rdg Rd, Underhill, VT 05489 | |
(802) 899-2790 | |
Not Available |
Full Name | Mr Gregory Mark Coleman |
---|---|
Gender | Male |
Speciality | Occupational Therapist |
Location | 59 Timber Rdg Rd, Underhill, Vermont |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1376691857 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
225X00000X | Occupational Therapist | 0720000390 (Vermont) | Primary |
Mailing Address | Practice Location Address |
---|---|
Mr Gregory Mark Coleman, OTR 59 Timber Rdg Rd, Underhill, VT 05489 Ph: (802) 899-2790 | Mr Gregory Mark Coleman, OTR 59 Timber Rdg Rd, Underhill, VT 05489 Ph: (802) 899-2790 |
News Archive
The spread of the deadly H5N1 strain of bird flu continues relentlessly across the world with the confirmation that dead swans found in Hungary and Croatia this week also succumbed to the virus.
This post on the Center for Strategic & International Studies' (CSIS) SmartGlobalHealth.org blog provides resources, including video and publications, related to a December 6 half-day seminar, sponsored by the CSIS Global Health Policy Center, that "focused on the activities, practices, and strategies that characterize the global health outreach of Brazil, China, India, Russia and South Africa, or the BRICS."
A new study from the University of Colorado Cancer Center finds that it is best if women who have to have both preventive gynecologic and breast surgeries have them done separately. The same dictum applies to breast reconstructive procedures following a mastectomy.
When it comes to risk disclosures made by drug companies in print and television ads, many consumers are not paying attention, according to a recent study by ORC Guideline (an infoGROUP company). The latest study in the company's Under the Skin series found that 41% of US consumers pay little or no attention to risk information presented by pharmaceutical companies in their TV commercials, and only half (50%) pay attention to such disclosures in print ads. This lack of attention is most prevalent among those 55 years of age or older.
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it initiated a Phase 1 clinical study of ISIS-PKKRx. ISIS-PKKRx is an antisense drug in development to treat patients with hereditary angioedemia (HAE).
› Verified 8 days ago